NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO, OR INVITATION TO, ACQUIRE OR SUBSCRIBE FOR ANY SECURITIES IN KAROLINSKA DEVELOPMENT AB (PUBL) IN ANY JURISDICTION. PLEASE ALSO REFER TO THE SECTION “IMPORTANT ...

Core Viewpoint - Karolinska Development AB has announced additional guarantee commitments of approximately 20 MSEK in its ongoing rights issue, bringing the total to approximately 115.2 MSEK, which covers about 57% of the rights issue volume [2][3]. Group 1: Rights Issue Details - The rights issue was resolved by the Board of Directors on December 1, 2025, and approved by the extraordinary general meeting on January 8, 2026, with a subscription period running until January 27, 2026 [2]. - The total rights issue amount is approximately 202.6 MSEK before issue costs [2]. - The Intermediate Guarantee covers the interval from approximately 47% to 57% of the rights issue, amounting to approximately 115.2 MSEK [3]. Group 2: Guarantee Commitments - Previously agreed guarantee commitments have increased from approximately 95.2 MSEK to approximately 115.2 MSEK [3]. - The guarantee commitments are not secured through bank guarantees or similar arrangements [5]. - A cash guarantee fee of 13% or a fee of 15% in newly issued shares will be paid for the Intermediate Guarantee [4]. Group 3: Shareholder Implications - Investors acquiring a shareholding of 10% or more of the total votes in the Company must notify the Inspectorate of Strategic Products prior to the investment [6]. - Any guarantee commitments that require approval under the Swedish Screening of Foreign Direct Investments Act are conditional upon obtaining such approval [6][19]. Group 4: Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing medical innovations [10]. - The company aims to build companies around leading scientists and management teams, co-funded by international investors [11]. - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for serious diseases [12].

Core Viewpoint - Karolinska Development AB is conducting a rights issue of series B shares amounting to approximately SEK 202.6 million, which has been approved by the Board of Directors and the extraordinary general meeting [2]. Group 1: Rights Issue Details - The rights issue is set to raise approximately SEK 202.6 million before transaction costs, as resolved by the Board on December 1, 2025, and approved on January 8, 2026 [2]. - An information document has been prepared in accordance with the Prospectus Regulation, detailing the terms and conditions of the rights issue, which has been registered with the Swedish Financial Supervisory Authority [3]. - The timetable for the rights issue includes trading in subscription rights from January 13 to January 22, 2026, and a subscription period from January 13 to January 27, 2026 [4]. Group 2: Advisory and Legal Support - Redeye AB is acting as the financial adviser, while Cirio Advokatbyrå AB serves as the legal adviser for the rights issue [5]. Group 3: Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations in the Nordic region [7]. - The company aims to create and grow companies that advance medical innovations into commercial products, benefiting patients and providing returns to shareholders [8]. - Karolinska Development has access to world-class medical innovations from leading universities and research institutes, aiming to build companies around top scientists supported by experienced management teams [9].

The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are invited to the Extraordinary General Meeting (“EGM”), on Thursday January 8, 2026, at 10.00 a.m. (CET), at Cirio Advokatbyrå, Biblioteksgatan 9, in Stockholm. The Board of Directors has resolved that shareholders shall have the right to exercise their voting rights through postal voting pursuant to item 13 in the Articles of Association. Therefore, shareholders may choose to exercise t ...

Core Viewpoint - Karolinska Development AB plans to conduct a rights issue of class B shares to raise approximately SEK 202.6 million for the continued development of existing investments, new investments, and general corporate purposes [2][4]. Rights Issue Details - The rights issue will consist of up to 675,193,985 new class B shares at a subscription price of SEK 0.30 per share, with an estimated transaction cost of SEK 16.8 million [4][9]. - Shareholders will have preferential rights, where one existing share grants five subscription rights, and two subscription rights allow for the purchase of one new class B share [4][9]. - The subscription period is from January 13, 2026, to January 27, 2026, with trading in subscription rights occurring from January 13 to January 22, 2026 [10][11]. Financial Commitments - Existing shareholders and members of the Board have committed approximately SEK 5.2 million, representing about 2.6% of the rights issue, while guarantee commitments total approximately SEK 95.2 million, or about 47% of the rights issue [3][12][13]. - The net proceeds will primarily be allocated to existing portfolio companies (approximately 75%) and general corporate purposes (approximately 25%) [10][8]. Company Background - Karolinska Development is an investment company focused on medical innovations with significant commercial potential, managing a portfolio of eleven companies, nine of which have drug candidates in clinical trials [6][7]. - The company aims to leverage its management expertise and co-investments with other investors to enhance the development and commercialization of its portfolio [7][23]. Extraordinary General Meeting - The rights issue is subject to approval by an Extraordinary General Meeting scheduled for January 8, 2026, which will also consider amendments to the company's articles of association and a proposed name change to KDventures AB [19][20].

Core Viewpoint - Ørsted, the world's largest offshore wind developer, will reduce its workforce by 2,000 positions by 2027, representing a quarter of its current roles, in response to various challenges and to enhance competitiveness in Europe [1][2]. Group 1: Workforce Reduction - Ørsted plans to cut approximately 2,000 jobs by the end of 2027 as part of its strategic focus on Europe and to improve competitiveness [1]. - The decision to reduce the workforce is linked to the completion of its large construction portfolio in the coming years, necessitating fewer employees [2]. Group 2: Financial Measures - Ørsted recently completed a rights issue, raising $9.35 billion (59.56 billion Danish crowns) from existing shareholders to address immediate financing needs and strengthen its capital structure [4][5]. - The rights issue was heavily discounted, priced at 66.60 crowns ($1.04) per share, compared to a closing price of 122.35 crowns ($19.18) [5]. Group 3: Industry Challenges - The offshore wind industry has faced significant challenges, including regulatory changes, cost inflation, and high interest rates, which have negatively impacted project economics [4]. - Ørsted has encountered difficulties in the U.S. market, particularly due to regulatory obstacles under the Trump Administration affecting offshore wind projects [3].

Company Actions - Orsted 的第三大股东计划参与该风力能源开发商的配股发行 [1]

Financial Strategy - Orsted 计划发行 94 亿美元（$9.4 billion）的股票[1] Project Funding - 该融资用于海上风电项目[1]

Core Viewpoint - Modus Therapeutics is conducting a fully secured rights issue to raise SEK 28.3 million for the continued development of its drug candidate sevuparin, aimed at treating chronic kidney disease with anemia [1][2][3]. Group 1: Rights Issue Details - The rights issue will provide SEK 28.3 million before issue costs, subject to approval at an extraordinary general meeting on July 29, 2025 [2][3]. - Major shareholders, including Karolinska Development, have committed SEK 17.7 million, covering 62.7% of the rights issue, with the remaining 37.3% underwritten by external parties [4]. Group 2: Purpose and Impact - The funds from the rights issue will be used to complete the ongoing clinical phase II study of sevuparin and to finance operations through the end of 2026 [3]. - The successful securing of the rights issue is viewed as a strong indicator of Modus Therapeutics' clinical strategy and financial health [5]. Group 3: Company Background - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations [6][7]. - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases, supported by experienced management teams and a strong global network [8].